ArticleLeukemia2018
The impact of individual comorbidities on non-relapse mortality following allogeneic hematopoietic stem cell transplantation.
Article in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 46 citations in OpenAlex.
- Renal dysfunction within 90 days of FluBu4 predicts early and late mortality.Bone marrow transplantation · 2019Trial
- Multicenter validation of the newly developed Concise Objectifiable Risk Evaluation (CORE) score also confirms its ability to complement the Hematopoietic Cell Comorbidity Index (HCT-CI).Bone marrow transplantation · 2026Article
- The Composite Health Risk Assessment Model (CHARM) Predicts Overall Mortality and Relapse, But Not Non-Relapse Mortality, in Adults Following Unrelated Single-Unit Cord Blood TransplantationTurkish journal of haematology : official journal of Turkish Society of Haematology · 2025Article
- The impact of individual comorbidities in transplant recipients receiving post-transplant cyclophosphamide.Bone marrow transplantation · 2025Article
- Allogeneic hematopoietic cell transplantation in elderly patients with myelodysplastic syndromes: Considerations and challenges.Seminars in hematology · 2024Review
- Influence of comorbidities on outcome in 1102 patients with an allogeneic hematopoietic stem cell transplantation.Bone marrow transplantation · 2024Article
- Comparative analysis of reduced toxicity conditioning regimens between fludarabine plus melphalan and fludarabine plus busulfex in adult patients with acute lymphoblastic leukemia.Bone marrow transplantation · 2024Article
- Reduced toxicity (FluBu3) versus myeloablative (BuCy) conditioning in acute myeloid leukemia patients who received first allogeneic hematopoietic stem cell transplantation in measurable residual disease-negative CR1.Bone marrow transplantation · 2024Article
- The sum of the parts: what we can and cannot learn from comorbidity scores in allogeneic transplantation.Hematology. American Society of Hematology. Education Program · 2023Review
- Prognostic Potential of Pulmonary Hypertension in Patients with Hematologic Malignancy.Advances in therapy · 2023Article
- Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP).Bone marrow transplantation · 2023Article
- Novel risk assessment for the intensity of conditioning regimen in older patients.Blood advances · 2023Article
- Comorbidities in transplant recipients with acute myeloid leukemia receiving low-intensity conditioning regimens: an ALWP EBMT study.Blood advances · 2023Article
- Impact of pre-transplant individual comorbidities on risk of ICU admission and survival outcomes following allogeneic hematopoietic stem cell transplantation.Bone marrow transplantation · 2023Article
- Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP).Bone marrow transplantation · 2022Article
- The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT.Blood advances · 2022Article
- Association of pre-existing comorbidities with outcome of allogeneic hematopoietic cell transplantation. A retrospective analysis from the EBMT.Bone marrow transplantation · 2022Article
- Conditioning Regimens for Frail Patients with Acute Leukemia Undergoing Allogeneic Stem Cell Transplant: How to Strike Gently.Clinical hematology international · 2021Review
- Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post-transplant cyclophosphamide.Cancer medicine · 2021Article
- Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend "when and for whom" in 2021?Haematologica · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Comorbidity burden is a well-established risk factor for non-relapse mortality (NRM) following allogeneic stem cell transplantation (allo-SCT). We evaluated whether individual comorbidities could better characterize NRM risk. Furthermore, given differing toxicity profiles of conditioning agents, we hypothesized that the hazard of comorbidities is exerted in a regimen-specific manner. This retrospective study included 875 adults treated with an allo-SCT. Six conditioning regimens were considered. Across the entire cohort and within each regimen, the hazard ratio (HR) for NRM associated with individual comorbidities was assessed using multivariable Cox regressions. In the overall population, renal dysfunction, hypoalbuminemia, and severe hepatic disease were associated with the highest risk of NRM (HR 2.1, HR 1.9, HR 1.7, respectively). The risk associated with specific comorbidities was modified by the conditioning regimen and was not correlated with intensity. In patients conditioned with fludarabine/busulfan (Flu/Bu4), NRM risk was increased with cardiac disease (HR 5.54). Severe pulmonary disease and a pre-existing infection were associated with increased NRM risk in patients receiving fludarabine/melphalan (HR 4.9) and fludarabine/treosulfan (HR 3.6), respectively. Comorbidities may exert effects unique to particular conditioning regimens, suggesting that regimen selection should be driven in part by specific comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.